R&D News | pharmaphorum

News

DeepMind applies its AI expertise to genetic diseases

Google’s DeepMind unit has used its artificial intelligence expertise to catalogue millions of ‘missense’ mutations in human DNA that may be related to the development of

News

Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

German group Merck has revved up its artificial intelligence-powered drug discovery with partnerships with two UK companies – Exscientia and BenevolentAI – that will focus

News

Novartis returns PD-1 antibody rights to BeiGene

BeiGene confirmed today that Novartis has pulled out of a partnership on PD-1 inhibitor tislelizumab, two and half years after paying $650 million upfront for ex-China rig

News

Older UK people back auto-enrolment in clinical trials

A new survey has found that a majority of people aged 50 or over in the UK who have long-term health conditions would have no problem with being automatically enrolled int

News

Anthos hails win over Xarelto with novel anticoagulant

Anthos Therapeutics says a phase 2b trial of its factor XI inhibitor anticoagulant abelacimab has been stopped early due to an “overwhelming” reduction in bleeding complic

News

US researchers start trials of universal flu vaccine

Researchers at the National Institutes of Health (NIH) have started dosing patients in a phase 1 trial of a new influenza vaccine candidate that aims to sidestep the annua

DeepMind applies its AI expertise to genetic diseases

Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

Novartis returns PD-1 antibody rights to BeiGene

Older UK people back auto-enrolment in clinical trials

Anthos hails win over Xarelto with novel anticoagulant

US researchers start trials of universal flu vaccine

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

How to meet your physicians where they are online

News

Editor's Picks